on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Appoints Dr. Michael Lock to Advisory Board
Onco-Innovations Limited has announced the appointment of Dr. Michael Lock to its Scientific and Clinical Advisory Board. With his extensive expertise in clinical trial design and multidisciplinary cancer care, Dr. Lock will support the company's development of innovative therapies, including the PNKP inhibitor program.
Dr. Lock, a Professor at Western University, has held significant roles in oncology leadership, such as Medical Director of the London Regional Cancer Program. His contributions to oncology, both internationally and domestically, have been recognized with awards like the Human Touch Award.
Thomas O'Shaughnessy, CEO of Onco-Innovations, emphasized Dr. Lock's valuable role in advancing the company's clinical development initiatives.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news